Pain Management

Canadian Submission Announced To Market Quadramet

Published in Cancer Weekly, March 24th, 1997

Cytogen Corp., Princeton, New Jersey, announced that it has submitted to the Canadian Health Protection Branch a New Drug Submission (NDS), for marketing approval of Quadramet in Canada.

Quadramet (Samarium 153-EDTMP) was developed to treat the severe pain associated with cancers that have spread to bone. Based on data from the World Health Organization (WHO), there are more than 30,000 new cases of such metastatic cancers in Canada each year.

Human clinical studies of Quadramet for the treatment of bone pain were conducted at over 40 leading medical institutions throughout North America and Europe. Four of the clinical studies contained in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry